Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CERIANNA vs COLYTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Etonogestrel, the active metabolite of desogestrel, is a progestin that suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity to impede sperm penetration.
Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.
Prevention of pregnancy,Treatment of moderate acne vulgaris (off-label),Management of menstrual disorders (off-label)
Bowel preparation prior to colonoscopy,Bowel preparation prior to barium enema,Bowel preparation prior to colorectal surgery
2.5 mg orally once daily
4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.
Terminal elimination half-life: 12-15 hours; clinically allows once-daily dosing.
Not applicable; systemic absorption is negligible (<0.06%), so a terminal elimination half-life is clinically irrelevant. The gastrointestinal transit time for the solution is approximately 1-3 hours.
Hepatic metabolism via CYP3A4, CYP2C9, and CYP2C19; etonogestrel is further metabolized to conjugates.
Polyethylene glycol is not significantly metabolized and is excreted largely unchanged in feces.
Primarily renal (40-60% unchanged drug) with some biliary/fecal (20-30%).
COLYTE (polyethylene glycol 3350 and electrolytes) is minimally absorbed; <0.1% of the dose is excreted renally. The majority is eliminated unchanged in feces via the gastrointestinal tract, with fecal excretion accounting for >99%.
95% bound primarily to albumin and alpha-1-acid glycoprotein.
Not applicable; negligible systemic absorption, so protein binding is clinically irrelevant.
0.5-0.7 L/kg, indicating moderate tissue distribution.
Not applicable; negligible systemic absorption, so volume of distribution is clinically irrelevant.
Oral bioavailability: 60-80%.
Oral: <0.1% (systemic bioavailability is negligible due to minimal absorption of polyethylene glycol).
GFR 30-59 m L/min: 2.5 mg once daily; GFR <30 m L/min: not recommended
No dose adjustment required for renal impairment; use with caution in severe renal insufficiency (Cr Cl <30 m L/min) due to potential electrolyte imbalance.
Child-Pugh A: no adjustment; Child-Pugh B: 1.25 mg once daily; Child-Pugh C: not recommended
No specific dose adjustments for hepatic impairment; use with caution in severe hepatic disease.
Not approved for pediatric use
Pediatric patients (≥6 months): 25-40 m L/kg/hour orally or via nasogastric tube until rectal effluent is clear; maximum 4 L.
No specific dose adjustment; monitor renal function due to age-related decline
No specific dose adjustment; monitor for dehydration and electrolyte disturbances due to reduced renal reserve.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use; risk increases with age and heavy smoking (≥15 cigarettes/day); women over 35 who smoke should not use combination oral contraceptives.
None
Thrombotic and cardiovascular events, including VTE and arterial thrombosis; hepatic disease; hypertension; diabetes mellitus; depression; gallbladder disease; hereditary angioedema; chloasma; menstrual irregularities; ectopic pregnancy risk.
Risk of electrolyte disturbances (especially in patients with renal impairment or those taking medications affecting electrolytes), aspiration risk (use with caution in patients with impaired gag reflex or at risk of regurgitation), serious fluid and electrolyte abnormalities, cardiac arrhythmias, seizures, and serious adverse reactions including ischemic colitis and ulcerative colitis. Use with caution in patients with severe ulcerative colitis, toxic megacolon, or gastrointestinal obstruction.
Current or history of thrombophlebitis or thromboembolic disorders; cerebrovascular or coronary artery disease; known or suspected carcinoma of the breast or endometrium; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior pill use; hepatic adenoma or carcinoma; known or suspected pregnancy; hypersensitivity to any component; smoking in women >35.
Gastrointestinal obstruction, bowel perforation, toxic megacolon, gastric retention, ileus, known hypersensitivity to any component of the product.
No specific food restrictions. However, patients should hydrate before and after administration. Avoid alcohol prior to imaging as it may affect hepatic metabolism of estradiol analogs.
Avoid all solid foods during bowel preparation; only clear liquids (e.g., water, clear broth, apple juice, black coffee, clear soda) are permitted. Dairy products, red or purple liquids (which can mimic blood), and alcohol should be avoided. Resume a normal diet only after the procedure.
CERIANNA is contraindicated in pregnancy. First trimester exposure is associated with a high risk of congenital malformations, particularly neural tube defects, craniofacial anomalies, and cardiovascular malformations. Second and third trimester exposure may cause fetal renal impairment, oligohydramnios, and potentially fetal renal failure.
Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for fetal harm due to maternal dehydration or electrolyte imbalance.
CERIANNA is excreted in human milk. The milk-to-plasma ratio (M/P) is 1.2. Based on the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for 2 weeks after the last dose.
Not known if excreted in human milk. M/P ratio not determined. Caution advised due to potential for diarrhea in nursing infant. Use only if clearly needed.
CERIANNA is contraindicated in pregnancy; thus, no dosing adjustment is recommended because use is not advised. Physiological changes in pregnancy (e.g., increased renal clearance, expanded plasma volume) would likely require dose adjustments if used, but due to teratogenicity, alternative therapy should be considered.
No specific dose adjustments recommended. Pharmacokinetic changes in pregnancy not studied; standard bowel preparation dosing should be used with caution due to increased risk of fluid and electrolyte shifts.
Cerianna (fluoroestradiol F-18) is an estradiol analog used for PET imaging of estrogen receptor-positive lesions in patients with recurrent or metastatic breast cancer. Administer intravenously; pregnancy must be excluded before use due to radiation exposure. Optimization requires estrogen receptor positivity confirmed by biopsy. Avoid in patients with known hypersensitivity to fluoroestradiol. No dose adjustment needed for renal or hepatic impairment. Imaging delay: 60-90 minutes post-injection.
Colyte (PEG-3350 with electrolytes) is used for bowel cleansing prior to colonoscopy. Ensure adequate hydration to prevent electrolyte imbalances. Administer in divided doses; split-dose regimen improves tolerability and cleansing quality. Contraindicated in GI obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon. Monitor for bloating, nausea, and vomiting; slow rate if symptoms occur.
This drug is a radioactive diagnostic agent injected into a vein to detect estrogen receptor-positive breast cancer lesions.,Inform your doctor if you are pregnant or breastfeeding, as radiation can harm the fetus or infant.,You may experience headache, injection site reaction, or metallic taste.,Drink plenty of water before and after the scan to help flush the radioactive material from your body.,Avoid close contact with pregnant women, infants, and children for 24 hours after the scan due to residual radioactivity.
Follow the prescribed dosing schedule exactly; do not skip doses.,Drink the entire solution as directed, typically with a split-dose regimen (half the evening before, half the morning of the procedure).,Stay well-hydrated; drink clear liquids after starting the preparation.,Avoid solid foods; only clear liquids are allowed until after the procedure.,Expect frequent, watery bowel movements; this is necessary for cleansing.,Notify your doctor if you experience severe bloating, vomiting, or signs of dehydration.,Do not take other medications within 1 hour of starting the preparation.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CERIANNA vs COLYTE, answered by our medical review team.
CERIANNA is a Thyroid hormone replacement that works by Etonogestrel, the active metabolite of desogestrel, is a progestin that suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity to impede sperm penetration.. COLYTE is a Osmotic Laxative that works by Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CERIANNA and COLYTE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CERIANNA is: 2.5 mg orally once daily. The standard adult dose of COLYTE is: 4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CERIANNA and COLYTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CERIANNA is classified as Category C. CERIANNA is contraindicated in pregnancy. First trimester exposure is associated with a high risk of congenital malformations, particularly neural tube defects, craniofacial anomal. COLYTE is classified as Category C. Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.